Shilpa Medicare Limited (BSE:530549) (NSE:SHILPAMED), an India-based API and formulation manufacturer, announced on Wednesday that it has received approval from the Subject Expert Committee (SEC) of India's Central Drugs Standard Organisation (CDSCO) for its Investigational New Drug (IND) application for Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg.
The product was recommended for marketing authorisation for treating non-alcoholic fatty liver disease (NAFLD).
Shilpa Medicare had earlier completed phase 3 clinical studies of this novel product SMLNUD07 -- Nor Ursodeoxycholic Acid (Nor UDCA) tablets -- and presented to the SEC the results of the trial titled 'A phase III, Randomized, Double- Blind, placebo controlled, multicentre, Parallel group study', evaluating the safety and efficacy of Nor-Ursodeoxycholic Acid 500 mg in patients with NAFLD.
The trial met all primary efficacy endpoints, demonstrating a significant improvement in fatty liver stage. Key findings included 83.3% of participants showing fibrosis reversal, with stabilisation in the rest, and elevated alanine transaminase (ALT) levels, a key NAFLD marker, normalised in approximately 90% of participants within 12 weeks.
The company said that these results position Nor UDCA as a breakthrough therapy for NAFLD, offering advantages over conventional UDCA, including enhanced choleretic effect, resistance to amidation, anti-inflammatory properties and fibrosis reduction.
Merck reports positive Phase 3 Data on HIV treatment DOR/ISL
Cantargia enrolls first patient in leukemia study with nadunolimab
Shilpa Medicare's Nor Ursodeoxycholic Acid Tablets IND receives regulatory approval in India
Centivax partners with Emery Pharma on universal flu vaccine
Hansa Biopharma completes enrolment for 20-HMedIdeS-19 PAES study
Arvinas and Pfizer report positive Phase 3 results for vepdegestrant in breast cancer trial
PHI advances Next-Generation HoloMonitor CellSync for cell and gene therapy
Gan & Lee doses first participant in Phase 2 clinical trial of bofanglutide injection
Health Canada approves Johnson & Johnson therapy for advanced EGFR-mutated lung cancer
Polarean expands Xenon MRI imaging for pharma-sponsored research
Immunome initiates Phase 1 trial of ROR1-targeted ADC IM-1021
Arrowhead Pharmaceuticals reports positive topline results for ARO-C3 in IgA nephropathy trial